Report overview
The global Recombinant Teriparatide for Injection market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Original Drug Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Recombinant Teriparatide for Injection include Eli Lilly and Company, LillyMedical, Ranbaxy Laboratories Ltd, Salubris, Shanghai United Cell Biological Engineering, Cadila Pharmaceuticals and Alkem Laboratories - AdisInsight
https, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Teriparatide for Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Teriparatide for Injection. This report contains market size and forecasts of Recombinant Teriparatide for Injection in global, including the following market information:
Global Recombinant Teriparatide for Injection Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global Recombinant Teriparatide for Injection Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five Recombinant Teriparatide for Injection companies in 2023 (%)
We surveyed the Recombinant Teriparatide for Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Teriparatide for Injection Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Recombinant Teriparatide for Injection Market Segment Percentages, by Type, 2023 (%)
Original Drug
Generic Drug
Global Recombinant Teriparatide for Injection Market, by Sales Channels, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Recombinant Teriparatide for Injection Market Segment Percentages, by Sales Channels, 2023 (%)
Hospital
Large Pharmacy
Others
Global Recombinant Teriparatide for Injection Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Recombinant Teriparatide for Injection Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Teriparatide for Injection revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Recombinant Teriparatide for Injection revenues share in global market, 2023 (%)
Key companies Recombinant Teriparatide for Injection sales in global market, 2019-2024 (Estimated), (K Units)
Key companies Recombinant Teriparatide for Injection sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly and Company
LillyMedical
Ranbaxy Laboratories Ltd
Salubris
Shanghai United Cell Biological Engineering
Cadila Pharmaceuticals
Alkem Laboratories - AdisInsight
https
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Teriparatide for Injection, market overview.
Chapter 2: Global Recombinant Teriparatide for Injection market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Teriparatide for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by sales channels, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Teriparatide for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Teriparatide for Injection capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
